TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01971840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI-KIDS
Description: MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
Study: NCT03619278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIVACAR
Description: Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 doses of 10-1074 antibodies and 3 doses of romidepsin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive 5 vaccines of placebo of HIVACAR01, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
Study: NCT03469934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etokimab
Description: Administered on Day 1 over 1 hour by IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered on Day 1 over 1 hour by IV infusion
Study: NCT02016573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal Denervation Catheter
Study: NCT02389062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.
Description: After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.
Description: After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.
Description: After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.
Study: NCT00747812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision
Description: Implantable Neurostimulator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Precision
Description: Implantable Neurostimulator
Study: NCT01517620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Glucosides Paeony Capsules
Description: Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
Study: NCT04208997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug
Description: Continuation of amiodarone or sotalol.
Study: NCT00183820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel, gemcitabine, and oxaliplatin
Description: 1. Paclitaxel 170 mg/m2 IV d 1 14 days~2. Gemcitabine 800 mg/m2 IV d 1 14 days~3. Oxaliplatin 100 mg/m2 IV d 1 14 days
Study: NCT04125888

Intervention type: DRUG
Intervention: Allergy immunotherapy (AIT)
Description: Immunotherapy for different types of allergies
Study: NCT05235048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Atraumatic tooth extraction without flap elevation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Atraumatic tooth extraction without flap elevation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Tooth extraction
Description: Atraumatic tooth extraction without flap elevation
Study: NCT02610556

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Intensity-modulated radiotherapy
Study: NCT04653909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The abdominal and back strengthening exercises on the mat, the open-closed perturbation training in sitting and standing positions for trunk control. Functional exercises were performed in the same positions for simulating daily living activities. The stretching and strengthening exercises were applied to her scoliosis and also given trunk orthoses.
Study: NCT03192982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-V impulse 6000 Series
Description: foot pad and pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment (compression)
Description: Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
Study: NCT02692339

Intervention type: DRUG
Intervention: Lenalidomide
Description: Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle

Intervention type: DRUG
Intervention: Dexamethasone
Description: Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
Study: NCT03448718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of \> 30 to \< 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
Study: NCT05235048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Atraumatic tooth extraction without flap elevation
Study: NCT00777491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction cisplatin
Description: 15 mg/m\^2 administered as a 60-minute infusion on days 1,2,3,8,9,10,15,16,17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction 5-fluorouracil
Description: 400mg/m\^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction gemcitabine
Description: 27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15, 18, 22, 25.
Study: NCT05235048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and socket seal with connective tissue graft
Description: Atraumatic tooth extraction without flap elevation and seal of the alveolar socket with connective tissue graft (microsurgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and socket seal with connective tissue graft
Description: Atraumatic tooth extraction without flap elevation and seal of the alveolar socket with connective tissue graft (microsurgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and socket seal with connective tissue graft
Description: Atraumatic tooth extraction without flap elevation and seal of the alveolar socket with connective tissue graft (microsurgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and socket seal with BRG and connective tissue graft and
Description: Atraumatic tooth extraction without flap elevation, position of a bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and socket seal with BRG and connective tissue graft and
Description: Atraumatic tooth extraction without flap elevation, position of a bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and socket seal with membrane placement, BRG and connective tissue graft
Description: Atraumatic tooth extraction without flap elevation, position of a collagen membrane and bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
Study: NCT01172522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04537429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: up to four iv infusions of eptinezumab
Study: NCT03219541

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interventional Automated mobile phone text
Description: Participants will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Automated mobile phone text
Description: Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
Study: NCT02284516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Lifitegrast Ophthalmic Solution 5%, BID for 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match active treatment, BID for 84 days
Study: NCT02198872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise, Aerobic (Water based)
Description: Patients of this group will be submitted to an aerobic water based physical training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land Group
Description: Patients of this group perform physical training on bicycle.
Study: NCT02863276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy
Study: NCT01422018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (bevacizumab)
Description: Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
Study: NCT01899664

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nerve Transfer Surgery
Description: Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
Study: NCT01979965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine (Active drug)
Description: Ranolazine therapy for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo therapy for three months
Study: NCT02048969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
Study: NCT03212690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local standard of care
Description: Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Description: Mechanical ventilation will be based on volume-assist control mode, with a target tidal volume of 6-8 milliliter per kg (mL/kg) and a target plateau pressure of 30 centimeter of water (cmH2O).
Study: NCT03282370

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JEVAX
Description: JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JECEVAX
Description: JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
Study: NCT01595633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switching from adefovir (10mg/day) to tenofovir (300mg/day)
Description: active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switching from adefovir (10mg/day) to tenofovir (300mg/day)
Description: active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
Study: NCT00936611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT03724786

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Six-hour urine protein collection
Description: This intervention includes the analysis of a 6-hour urine collection for protein, to serve for a calculated 24-hour result, according to which pregnancy will be managed.
Study: NCT03748108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
Study: NCT03949439

Intervention type: PROCEDURE
Intervention: Elective Cardiac Surgery
Description: Surgical interventions (coronary artery bypass \[CAB\], valve replacement or valve repair).

Intervention type: PROCEDURE
Intervention: Elective Cardiac Surgery
Description: Surgical interventions (coronary artery bypass \[CAB\], valve replacement or valve repair).
Study: NCT01015599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOP'N After-school Program
Description: Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
Study: NCT01781754

Intervention type: PROCEDURE
Intervention: Blood withdrawal
Description: This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
Study: NCT00147212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET 743
Description: ET-743 administered IV by 24-hr infusion every 3 weeks
Study: NCT01880619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Patients in this arm will receive Tamsulosin 0.4 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin
Description: Patients in the arm will receive Solifenacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients in this are will receive placebo
Study: NCT03014557

Intervention type: DEVICE
Intervention: left atrial appendage closure device implantation
Description: to permanently implant a WATCHMAN left atrial appendage closure device through trans-catheter approach
Study: NCT01423578

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hatha Yoga (HY)
Description: 3 Sessions of yoga instruction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Exercise (CE)
Description: 3 sessions of cardiovascular exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: 4 smoking cessation counseling visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: 4 smoking cessation counseling visits.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking Cessation Counseling
Description: 4 smoking cessation counseling visits.
Study: NCT01293773

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Element stent
Description: paclitaxel-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integrity Resolute stent
Description: ABT 578-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Prime stent
Description: Everolimus-eluting stent
Study: NCT01022749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine anti-H1N1
Description: patients who received the vaccine anti-H1N1
Study: NCT02295410

Intervention type: BEHAVIORAL
Intervention: CPT
Study: NCT00519454

Intervention type: OTHER
Intervention: Peripheral lab draws
Description: 100ml blood for analysis, taken no more than 4 times in one year.
Study: NCT02162316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motilitone®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-Cilin®, Clari® and Pantoline®
Study: NCT02702453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: website
Description: The intervention arm will consist of 12 modules, 8 of which are consistent with the trajectory of prostate cancer and its treatment. Four modules address aspects of the prostate cancer experience that are important for patients and partners as well as providers and are designed to optimize the goal of supporting patients and partners in their sexual recovery.
Study: NCT03439917

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Carnitine tartrate
Description: 2g L-Carnitine tartrate as a powder consumed twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal Replacement Drink
Description: 325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Meal Replacement Drink
Description: 325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day
Study: NCT04314934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73
Description: Oral capsules
Study: NCT02489760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: The treatment arm will receive adalimumab 40 mg subcutaneously biweekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: The treatment arm will receive adalimumab 40 mg subcutaneously biweekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: The control arm will continue etanercept 25 mg subcutaneously twice a week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: The control arm will continue etanercept 25 mg subcutaneously twice a week
Study: NCT04214171

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait and muscle strength will be assessed
Description: The extensor moment of the hip during gait and evaluation of the muscular strength of the hip will be evaluated

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait and muscle strength will be assessed
Description: The extensor moment of the hip during gait and evaluation of the muscular strength of the hip will be evaluated

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait and muscle strength will be assessed
Description: The extensor moment of the hip during gait and evaluation of the muscular strength of the hip will be evaluated

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait and muscle strength will be assessed
Description: The extensor moment of the hip during gait and evaluation of the muscular strength of the hip will be evaluated
Study: NCT00777491

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Induction BID radiation therapy
Description: Twice daily (BID) on days 1-5,8-12,15-17. The first daily treatment consists of 1.6 Gy delivered to the pelvis. The second fraction consists of 1.5 Gy to the bladder for the first 5 treatment days. Then, 1.5 Gy is delivered to bladder tumor volume as the second treatment for the remaining 8 treatment days. The bladder tumor volume receives a total of 40.3 Gy.
Study: NCT04511104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance and aerobic exercise in addition to standard of care rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care rehabilitation
Study: NCT02327689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine plus adefovir dipivoxil
Description: emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine plus adefovir dipivoxil
Description: emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
Study: NCT03250221

Intervention type: DEVICE
Intervention: barbed sutures
Description: Use of the barbed sutures for robotic or laparoscopic myomectomy

Intervention type: DEVICE
Intervention: Vicryl@ suture
Description: Use of Vicryl@ suture for robotic or laparoscopic myomectomy